MSR19 A Matching-Adjusted Indirect Comparison of Asciminib Versus Ponatinib, Nilotinib and Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients after ≥2 Tyrosine Kinase Inhibitors

Autor: EL Atallah, V Maheshwari, MJ Mauro, C Boquimpani, D Réa, A Hochhaus, Y Minami, L Saini, R Corbin

Publikováno v: Value in Health. 25:S521

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9ac92f84782d3e3178e0179cc0d827f
https://doi.org/10.1016/j.jval.2022.04.1226

BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.

Autor: Kockerols C; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands., Valk PJM; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., Dulucq S; Laboratory of Hematology, Hôpital Haut Lévêque, University hospital of Bordeaux, Pessac, France., Nicolini FE; Department of Hematology, Centre Léon Bérard and CRCL, Lyon, France., Mahon FX; Department of Hematology, Institut Bergonié, Bordeaux, France.; INSERM Unit BRIC 1312, Bordeaux University, Bordeaux, France., Atallah E; Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA., Mauro MJ; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Radich JP; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Bernardi S; Department of Clinical and Experimental Sciences, Hematology 2 and Bone Marrow Transplant Center, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy., Russo D; Department of Clinical and Experimental Sciences, Hematology 2 and Bone Marrow Transplant Center, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy., Farina M; Department of Clinical and Experimental Sciences, Hematology 2 and Bone Marrow Transplant Center, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy., Mori S; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy., Gambacorti-Passerini C; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.; Department of Hematology, S. Gerardo Hospital, Monza, Italy., Civettini I; Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.; Department of Hematology, S. Gerardo Hospital, Monza, Italy., Lu L; South Australia Health and Medical Research Institute, University of Adelaide Medical School and Precision Cancer Medicine Theme, Adelaide, Australia., Yeung D; South Australia Health and Medical Research Institute, University of Adelaide Medical School and Precision Cancer Medicine Theme, Adelaide, Australia., Branford S; Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.; Clinical and Health Sciences, University of South Australia, Adelaide, Australia.; School of Medicine, The University of Adelaide, Adelaide, Australia., Colafigli G; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Breccia M; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Hogenbirk P; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., van Rosmalen J; Department of Biostatistics, Erasmus University Medical Center, Rotterdam, The Netherlands.; Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands., Cornelissen JJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands., Westerweel PE; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Aug; Vol. 99 (8), pp. 1632-1635. Date of Electronic Publication: 2024 May 20.

Project Confirm: Accelerated Drug Approvals for CML-Response.

Autor: Sweet KL; Moffitt Cancer Center, Tampa, Florida., Cortes JE; Georgia Cancer Center, Augusta University, Augusta, Georgia., Apperley JF; Centre for Haematology, Imperial College, London, United Kingdom., Mann M; Patient Advocate, Jonesboro, Georgia., Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York City, New York., Oehler VG; Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, Washington., Ruiz C; Patient Advocate, Jonesboro, Georgia., Schiffer CA; Department of Hematology-Oncology, Karmanos Cancer Center at Wayne State University, Detroit, Michigan., Ehrlich LA; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Pamuk GE; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Wynne J; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Mehta GU; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Okusanya OO; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., de Claro RA; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia., Theoret MR; Oncology Center of Excellence, FDA, Washington, District of Columbia., Smith BD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland., Norsworthy KJ; Center for Drug Evaluation and Research, FDA, Washington, District of Columbia.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jan 05; Vol. 30 (1), pp. 237-238.

Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.

Autor: Shah NP; UCSF School of Medicine, San Francisco, California, USA., García-Gutiérrez V; Servicio Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Jiménez-Velasco A; Servicio de Hematología y Hemoterapia, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain., Larson SM; David Geffen School of Medicine at UCLA, Los Angeles, California, USA., Saussele S; Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany., Rea D; Adult Hematology Department, Hôpital Saint-Louis, Paris, France., Mahon FX; Institut Bergonié Cancer Center, Université Bordeaux, Bordeaux, France., Levy MY; Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA., Gómez-Casares MT; Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain., Mauro MJ; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Sy O; Bristol Myers Squibb, Princeton, New Jersey, USA., Martin-Regueira P; Bristol Myers Squibb, Princeton, New Jersey, USA., Lipton JH; Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Publikováno v: British journal of haematology [Br J Haematol] 2023 Sep; Vol. 202 (5), pp. 942-952. Date of Electronic Publication: 2023 May 29.

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.

Autor: Atallah E; Medical College of Wisconsin, Milwaukee, WI, USA. eatallah@mcw.edu., Mauro MJ; Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Hochhaus A; Universitätsklinikum Jena, Jena, Germany., Boquimpani C; HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil.; Oncoclínica Centro de Tratamento Oncológico, Rio de Janeiro, Brazil., Minami Y; National Cancer Center Hospital East, Kashiwa, Japan., Maheshwari VK; Novartis Healthcare Pvt. Ltd, Hyderabad, India., Saini L; Novartis Healthcare Pvt. Ltd, Hyderabad, India., Corbin R; Novartis Services Inc., East Hanover, NJ, USA., Réa D; Adult Hematology Hôpital Saint-Louis and FiLMC, Paris, France.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2023 Aug; Vol. 149 (9), pp. 6247-6262. Date of Electronic Publication: 2023 Jan 28.